Home Abortion Tags

Abortion

"KFF graphic with white text on a purple background that reads "Interactive Dashboard: Abortion in the United States." The graphic also has photo illustrations of the Supreme Court and abortion medication."

The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →

View the Latest: Abortion

Filter

List Grid

11 - 20 of 294 Results

  • Out-of-Pocket Costs for Long-Acting Reversible Contraception Among Individuals Enrolled in Employer Sponsored Insurance Plans

    Perspective

    In this analysis, published in the journal Contraception, KFF’s Linda Li, Brittni Frederiksen, and Alina Salganicoff look at intrauterine device (IUD) and contraceptive implant insertion-related costs among privately insured individuals to better understand why patients are experiencing unexpected expenses for what should be fully covered contraceptive services under the ACA.

  • Supreme Court Leaves Mifepristone Access Unchanged – For Now

    Quick Insights

    In addition to ongoing litigation, last September the Trump administration FDA, after  requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety.  This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear. 

  • Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court

    Issue Brief

    This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the other pending litigation involving mifepristone, and the mounting tension between states seeking to protect abortion and the states banning the provision of abortion.

  • Abortion Coverage Limitations in Medicaid and Private Insurance Plans

    Issue Brief

    This brief reviews current federal and state policies on Medicaid and insurance coverage of abortion services in the U.S. and presents national and state estimates on the availability of abortion coverage for people enrolled in private plans, Marketplace plans, and Medicaid.

  • Abortion in the United States Dashboard

    Feature

    The Abortion in the U.S. Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade.

  • UNFPA Funding and Kemp-Kasten: An Explainer

    Issue Brief

    This fact sheet provides an overview of the history of the Kemp-Kasten amendment, which states that no U.S. funds may be made available to “any organization or program which, as determined by the president of the United States, supports or participates in the management of a program of coercive abortion or involuntary sterilization,” and examines its current application. Since enacted in 1985, Kemp-Kasten has often been used to withhold funding from the United Nations Population…

  • The Latest on Medication Abortion Access: The Court Awaits the FDA Review

    Quick Insights

    Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.